Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KHN922 in Advanced Solid Tumors
NCT07514975Phase 2Not yet recruiting
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of KHN922 in solid tumor (advanced stage), sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd.. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
KHN922
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07514975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07514975.